» Articles » PMID: 20861127

Prognosis of Heart Failure Patients with Reduced and Preserved Ejection Fraction and Coexistent Chronic Obstructive Pulmonary Disease

Overview
Publisher Wiley
Date 2010 Sep 24
PMID 20861127
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The long-term prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFPEF) and coexistent chronic obstructive pulmonary disease (COPD) has not been previously investigated. The primary aim of this study was to determine whether the long-term prognosis of HFPEF patients with COPD differs from that of heart failure patients with reduced left ventricular ejection fraction (HFREF) and COPD. The secondary aim was to identify independent predictors of event-free survival in patients with HF and COPD.

Methods And Results: We investigated 184 patients with coexistent HF and COPD. Heart failure with preserved left ventricular ejection fraction was present in 98 cases (53%) and HFREF in the remaining 86 cases (47%). Mean follow-up time was 731±369 days. Cardiovascular/pulmonary hospitalization or mortality occurred in 71 patients (39%). No significant difference was observed between the two study groups in terms of event-free survival (P=0.457), but event-free survival was found to be independently associated with New York Heart Association (NYHA) class [III vs. I, hazard ratio (HR) 2.92, 95% confidence interval (CI) 1.09-7.82], Global initiative for chronic Obstructive Lung Disease (GOLD) stage (III vs. I, HR 3.20, 95% CI 1.33-7.68), systemic hypertension (SHT; HR 2.99, 95% CI 1.41-6.33), and pulmonary hypertension (PH; HR 4.35, 95% CI 1.95-9.68).

Conclusion: In HF patients with coexisting COPD, cardiovascular and pulmonary event-free survival of HFPEF was found to be similar to that of HFREF over 3 years follow-up. Furthermore, severe NYHA class, severe GOLD stage, SHT, and PH were found to be independent predictors of event-free survival.

Citing Articles

Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.

Papaporfyriou A, Bartziokas K, Gompelmann D, Idzko M, Fouka E, Zaneli S Life (Basel). 2023; 13(6).

PMID: 37374082 PMC: 10301030. DOI: 10.3390/life13061299.


Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction.

Lin C, Yeh J, Lin T, Lo Y, Chang B, Ju J BMC Pulm Med. 2023; 23(1):67.

PMID: 36805703 PMC: 9936736. DOI: 10.1186/s12890-023-02357-z.


Chronic Obstructive Pulmonary Disease in Elderly Patients with Acute and Advanced Heart Failure: Palliative Care Needs-Analysis of the EPICTER Study.

Mendez-Bailon M, Lorenzo-Villalba N, Romero-Correa M, Josa-Laorden C, Inglada-Galiana L, Menor-Campos E J Clin Med. 2022; 11(13).

PMID: 35806992 PMC: 9267665. DOI: 10.3390/jcm11133709.


Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register.

Arcoraci V, Squadrito F, Rottura M, Barbieri M, Pallio G, Irrera N Front Cardiovasc Med. 2022; 9:876693.

PMID: 35651906 PMC: 9149000. DOI: 10.3389/fcvm.2022.876693.


The clinical characteristics and outcomes of heart failure patient with chronic obstructive pulmonary disease from the Japanese community-based registry.

Takabayashi K, Terasaki Y, Okuda M, Nakajima O, Koito H, Kitamura T Heart Vessels. 2020; 36(2):223-234.

PMID: 32770265 DOI: 10.1007/s00380-020-01675-0.